Atezolizumab–nab-paclitaxel improves PD-L1-positive metastatic TNBC survival

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 24 / Springer Healthcare

Atezolizumab–nab-paclitaxel improves PD-L1-positive metastatic TNBC survival

Oncology Breast Cancer ESMO-2020

Description

Leisha Emens takes us through the final overall survival analysis of the IMpassion130 study supporting the use of atezolizumab plus nab-paclitaxel in certain subsets of patients with metastatic triple-negative breast cancer, and outlines the key unmet needs.

Related Content

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.